Discovery and Evaluation of TLR-Targeted Immune Agonists-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery and Evaluation of TLR-Targeted Immune Agonists

Published:2024-09-05 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chernyak Natalia¹^ORCID,Bhagwat Bhagyashree²,Naravula Saraswathi²,Chen Ying³,Solban Nicolas⁴,Zhang Fan²,Kofman Esther²,Raoufi Fahimeh²,Dang Xibei³^ORCID,Bao Jianming¹,Tomazela Daniela²,Baily Marc²,Geierstanger Bernhard²,Flygare John A.¹,Han Jin-Hwan⁵,Willingham Aarron²,Seganish W. Michael¹^ORCID

Affiliation:

1. Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States

2. Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States

3. Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., South San Francisco, California 94080, United States

4. Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States

5. Discovery Oncology, Merck & Co., Inc., South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00804

Reference54 articles.

1. A decade of immune-checkpoint inhibitors in cancer therapy

2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

3. Immune Checkpoint Inhibitors in Cancer Therapy

4. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP